返回
NRX Pharmaceuticals Inc（NRXP）價格
NRXP 股價走勢圖
NRXP 財務
NRX Pharmaceuticals Inc
$2.27
5.58%
$0.12
收盤價：Jan 16, 16:00:00 GMT-5
$2.2
-3.06%
$-0.06
盤前：Jan 20, 09:00:14 GMT-5
關鍵數據
前收市價
$2.15
開盤價
$2.18
當日範圍
$2.15 - $2.38
52週區間
$1.58 - $4.27
交易量
1.5M
平均成交量
862.1K
每股盈餘 (TTM)
-2.32
股息收益率
--
市值
$61.8M
什麼是 NRXP？
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.